| D |
|
Dabigatran etexilate 150 mg once daily for the prevention of venous thromboembolism after total knee or hip replacement surgery in the elderly and those with moderate renal impairment
|
| Dahl O.E., Kurth A.A., Rosencher N., Clemens A., Feuring M., Noack H., Eriksson B.I. |
| |
|
Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study
|
| Hamed M., Gambert S., Bliden K., Bailon O., Singla A., Antonino M., Hamed F., Tantry U., Gurbel P.A. |
| |
|
Daunorubicin enhances procoagulant activity of RBC
|
| Zhou J., Zheng Y., Li H., Fu Y., Li W., Zhang X., Hou J., Gilbert G.E., Shi J. |
| |
|
D-Dimer (DD) levels at diagnosis in relation to the site and extension of leg deep vein thrombosis (DVT)
|
| Legnani C., Cini M., Cavallaroni K., Rodorigo G., Cavazza S., Valdrč L., Amato A., Palareti G. |
| |
|
D-dimer and age as risk factors for recurrence after a first episode of venous thromboembolism in the extended follow-up of the prolong study
|
| Cosmi B., Legnani C., Pengo V., Ghirarduzzi A., Testa S., Alatri A., Domenico P., Poli D., Tripodi A., Palareti G. |
| |
|
D-dimer and clinical probability to rule out pulmonary embolism in cancer patients: an explorative study to increase the clinical utility
|
| van Sluis G.L., Douma R.A., Sohne M., Kamphuisen P.W., Leebeek F.W.G., Buller H.R. |
| |
|
D-dimer and comorbidities as risk factors for recurrence after a first episode of venous thromboembolism in the extended follow-up of the prolong study
|
| Cosmi B., Legnani C., Pengo V., Ghirarduzzi A., Testa S., Alatri A., Prisco D., PoliPOLI D., Tripodi A., Palareti G. |
| |
|
D-dimer and sex as risk factors for recurrence after a first episode of venous thromboembolism in the extended follow-up of the prolong study
|
| Cosmi B., Legnani C., Pengo V., Tosetto A., Ghirarduzzi A., Alatri A., Prisco D., Poli D., Tripodi A., Palareti G. |
| |
|
D-dimer and short-term clinical outcome of pulmonary embolism: role of pulmonary artery clot load
|
| Grau E., Santos M., Garcia R., Ferrer J., Isarria S., Sanchez J., Selfa S., Molina R., Tenias J. |
| |
|
D-dimer as a possible prognostic marker of breast cancer in hormonal receptor negative patients
|
| Carvalho M.G., Fernandes A.P., Figueiredo C.P., Bueno E.C., Ribeiro M.A., Gomes K.B., Dusse L.M.S., Batschauer A.P.B. |
| |
|
D-dimer concentrations in umbilical cord blood of normal neonates
|
| Grau E., Correcher P., Tenias J., Garcia R., Santos M., Monteagudo E., Calvo F. |
| |
|
D-dimer test for diagnosis of deep venous thrombosis (DVT) in the ICU
|
| Moroi R., Yaguchi A., Takeda M., Abe M., Harada T., Yamaki T. |
| |
|
D-dimer time course after stopping anticoagulation after a first episode of idiopathic venous thromboembolism: the PROLONG II prospective study
|
| Cosmi B., Legnani C., Tosetto A., Pengo V., Ghirarduzzi A., Alatri A., Testa S., Prisco D., Poli D., Tripodi A., Palareti G. |
| |
|
D-dimer to predict thrombosis recurrence after unprovoked venous thromboembolism: effect of patient- and D-dimer-related factors on recurrence prediction
|
| Iorio A., Douketis J., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Tosetto A. |
| |
|
D-dimer to predict thrombosis recurrence: comparison of aggregate data and individual patient data meta-analyses
|
| Marcucci M., Iorio A., Douketis J., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Tosetto A. |
| |
|
Decrease factor VIIA/antithrombin complexes in children with ischemic stroke
|
| Spiezia L., Rossetto V., Gavasso S., Tognin G., Brandolin B., Woodhams B., Simioni P. |
| |
|
Decrease of intraoperative transfusion, especially fresh frozen plasma, during cardiovascular surgery leads to decrease the risk of the postoperative infection
|
| Iwade M., Nomura M., Iwade K. |
| |
|
Decreased expression of MBD2 and MBD4 gene and genomic-wide hypomethylation in patients with idiopathic thrombocytopenic purpura
|
| Chen Z., Gu D., Chen X., Zhou Z., Guo Z., Ge J., Zhao H., Yang R. |
| |
|
Decreased global fibrinolytic capacity in children post cardiopulmonary bypass surgery for repair of congenital heart defects: a prospective cohort study
|
| Mitchell L.G., Dietrich K., Rebeyka I., Ross D., Qayyum S. |
| |
|
Decreased heme oxygenase-1 expression in patients with pulmonary hypertension following pulmonary embolism
|
| Marchick M.R., Kline J.A. |
| |
|
Decreased levels of platelet protein S in patients under treatment with warfarin
|
| Bulato C., Radu C., Gavasso S., Tognin G., Spiezia L., Zerbinati P., Simioni P. |
| |
|
Decreased overall survival and increased risk of thrombosis in children with cancer and central venous line (CVL) dysfunction
|
| Athale U., Siciliano S., Cheng J., Thabane L., Chan A.K.C. |
| |
|
Decreased plasma soluble rage in patients with hypercholesterolemia: effects of statins
|
| Vazzana N., Santilli F., Bucciarelli L.G., Noto D., Cefalů A.B., Davě V., Ferrante E., Pettinella C., Averna M., Ciabattoni G., Davě G. |
| |
|
Decreasing warfarin sensitivity during the first 3 months after heart valve surgery: implications for dosing
|
| Meijer K., Kim Y., Schulman S. |
| |
|
Deep vein thrombosis – what lies beneath?
|
| Braude P., Prathibha B. |
| |
|
Deep venous thromboembolism in a patient of factor V deficiency
|
| Nishiya K., Nogami K., Kikukawa Y., Shinozawa K., Yada H., Fukutake K., Shima M. |
| |
|
Defibrotide augments the anticoagulant actions of heparin and low molecular weight heparins
|
| Fareed J., Cunanan J., Hoppensteadt D., Iqbal O., Adiguzel C. |
| |
|
Defibrotide blunts the pro-thrombotic effect of thalidomide on endothelial cells
|
| Echart C., Somaini S., Richardson P.G., Fareed J., Iacobelli M. |
| |
|
Deficiency of plasminogen activator inhibitor type 1 (PAI-1) and alpha2-antiplasmin (APL) activity in patients with a bleeding tendency of unknown origin
|
| Haselböck J., Laczkovics C., Ay C., Simanek R., Quehenberger P., Pabinger I. |
| |
|
Deficiency of von Willebrand factor protects mice from ischemic stroke
|
| De Meyer S.F., Kleinschnitz C., Schwarz T., Austinat M., Vanhoorelbeke K., Nieswandt B., Deckmyn H., Stoll G. |
| |
|
Defining human endothelial progenitor cells
|
| Yoder M.C. |
| |
|
Defining the function of novel platelet genes using a laser thrombosis model in danio rerio
|
| Salles I.I., O’Connor M.N., Cvejic A., Watkins N.A., Burns P., Walker A., Garner S.F., Jones C.I., Macaulay I.C., Steward M., Zwaginga J., Bray S.L., Dudbridge F., de Bono B., Goodall A.H., Deckmyn H., Stemple D.L., Ouwehand W.H., on behalf of the Bloodomics Consortium |
| |
|
Definition of the thrombin-binding site on the human factor VIII C2 domain
|
| Lin J.C., Schuman J., Nakaya S.M., Pratt K.P. |
| |
|
Delay in initiating prophylactic treatment with dabigatran etexilate following total hip or knee replacement surgery did not affect efficacy. Pooled analysis of two European phase III trials
|
| Dahl O.E., Kurth A.A., Rosencher N., Schnee J.M., Clemens A., Hantel S., Eriksson B.I. |
| |
|
Demographic features, functional status and outcomes of a large sample of patients diagnosed with pulmonary embolism in emergency departments in the United States
|
| Hernandez J., Pollack C.V., Kline J.A., Hiestand B., Slattery D., Schrieber D., Pendleton R. |
| |
|
Dendritic cells (DCS) differentiated from circulating hematopoietic progenitor cells (HPCS), induced by CD4+ T cells is responsible for inhibition of regulatory T cells (TREGS) in atherosclerosis
|
| Chen D., Lu X., Kakkar V. |
| |
|
Dental disease in type 3 von Willebrand Disease; a neglected problem
|
| Seary M.E., Winter L., Judd P., Casas M.J., Stain A.M., Carcao M.D. |
| |
|
Depletion of antioxidant capacity in hyperhomocysteinemic patients with peripheral arterial occlusive disease.
|
| Shmeleva V.M., Rybakova L.P. |
| |
|
Depletion of neutralizing anti-ADAMTS13 antibody from acquired TTP patient plasma by ADAMTS13-specific affinity adsorption
|
| Plaimauer B., Skalicky S., Schmidt M., Hasslacher M., Scheiflinger F. |
| |
|
Derivation of a clinical prediction rule that includes D-dimer to identify high-risk patients with pulmonary embolism: findings from the riete registry
|
| Grau E., Tenias J., Ferrer J., Guil M., Sanchez R., Riera A., Sahuquillo J., Vasco B. |
| |
|
Derivation of a model for predicting the warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized initiation nomogram
|
| Lazo-Langner A., Monkman K., Kovacs M.J. |
| |
|
Design of a recombinant antithrombin variant as a potent antidote for fondaparinux and other heparin derivatives
|
| Bianchini E.P., Picard V., Fazavana J., Borgel D. |
| |
|
Detecting tissue factor-positive cells in a mixed population by scanning electron microscopy
|
| Strogolov V., Westrick L.G., Oliver J.A. |
| |
|
Detection and characterization of von Willebrand disease: a crucial step prior to major surgery
|
| Proulle V., Boutekedjiret T., Pottecher J., Court C., Missenard J., Dreyfus M. |
| |
|
Detection of 101 novel mutations in the factor 8 gene of Iranians hemophilia A patients
|
| Ravanbod S., Rastegarlari G., Rassoulzadegan M., Ala F., Enayat S. |
| |
|
Detection of anti platelet factor 4/heparin antibodies using commercial elisa assays
|
| Riddell A.F., Brooks S., Davenport A., Chowdary P. |
| |
|
Detection of canine coated platelets by three color flow cytometry
|
| Knudsen T., Kjalke M., Tranholm M., Jensen A.L., Kristensen A.T. |
| |
|
Detection of duplications and deletions within the factor VIII gene by MPLA
|
| Bignell P.A., Keeling D., Giangrande P. |
| |
|
Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay
|
| Ollivier V., Manly D.A., Wang J., Machlus K.R., Wolberg A.S., Jandrot-Perrus M., Mackman N. |
| |
|
Detection of F8 mutations by high resolution melting (HRM) analysis
|
| Bignell P.A., Keeling D., Giangrande P. |
| |
|
Detection of large rearrangements by MLPA in severe hemophilia A patients
|
| Lannoy N., Abinet I., Lambert C., Vermylen C., Dahan K., Hermans C. |
| |
|
Detection of P2Y14 receptor protein on platelets and investigation of the role of P2Y14 in platelet function
|
| Dovlatova N., Wijeyeratne Y.D., Fox S.C., Manolopoulos P., Johnson A.J., White A.E., Latif L., Ralevic V., Heptinstall S. |
| |
|
Detection of PrPSc in the spleen of an adult haemophilic patient in the UK
|
| Ironside J.W., Peden A., Head M.W., Keeling D.M., Millar C.M., Hill F.G.H. |
| |
|
Detection of pulmonary emboli with 99mTC-labeled anti-fibrin fab’ fragments (thromboview): phase II study
|
| Morris T.A., Gerometta M., White R.H., Yusen R.D., Douketis J.D., Kaatz S.S., Ginsberg J.S. |
| |
|
Detection of pulmonary embolism with pulmonary MDCT-angiography or ventilation/perfusion SPECT combined with low-dose CT
|
| Mortensen J., Gutte H., Jensen C.V., Recke Pvd , Petersen C.L., Kjćrgaard J., Kristoffersen U.S., Kjćr A. |
| |
|
Detection of tissue factor activity in whole blood by a fluorogenic thrombin generation assay
|
| Coll E., Amirkhosravi A., Francis J. |
| |
|
Detection of type 1 von Willebrand Disease with increased von Willebrand Factor clearance
|
| Meiring M., Setlaba P., Coetzee M. |
| |
|
Determinants of carotid intima-media thickness among HIV positive persons: a three years prospective cohort study
|
| Fourn E., Pasquier E., Delluc A., Bressollette L., de Saint Martin L. |
| |
|
Determinants of high protein C levels in a large Dutch family
|
| Roshani S., Pintăo M.C., de Visser M.C.H., Tieken C., Tanck M.W., Büller H.R., Wichers I.M., Meijers J.C.M., Middeldorp S., Reitsma P.H. |
| |
|
Determinants of residual platelet reactivity in a cohort of 750 stable cardiovascular patients treated with aspirin and/or clopidogrel: insight from the adrie study on stable cardiovascular patients.
|
| Fontana P., Barazer I., Castelli C., Nolli S., Berdagué P., Fabbro-Peray P., Schved J., Bounameaux H., Mach F., de Moerloose P., Reny J. |
| |
|
Determinants of thrombin generation in acute myocardial infarction
|
| Smid M., Dielis A.W.J.H., van Oerle R., Govers-Riemslag J.W.P., Spronk H.M.H., Hamulyák K., Prins M., Rosing J., Waltenberger J., ten Cate H. |
| |
|
Determination and differentiation of aspirin and clopidogrel effectiveness by 96-well plate aggregometry and measurement of thrombi adhesion
|
| Armstrong P.C.J., Dhanji A.A., Truss N.J., Zain Z.N.M., Tucker A.T., Mitchell J.A., Warner T.D. |
| |
|
Determination of activated factor XIII in plasma as a marker of activation of coagulation
|
| Mirshahi S., Soria C., Chidiac J., Kierzek G., Varin R., Batista R., Drouet L., Woodhams B.J., Soria J. |
| |
|
Determination of adamts-13 and vWF antigen and activity levels in patients with thrombotic thrombocytopenic purpura and other thrombocytopenic disorders in kuwait
|
| Jadaon M.M., Al-Awadhi A.M., Al-Jafar H.A., Al-Wazzan H.J. |
| |
|
Determination of PT-INR by new portable device (CoaguCheck XS)
|
| Iwahashi H., Tashiro T., Morishige N., Tacheuchi K., Nishimi M., Hayashida Y., Ito N., Kuwahara G. |
| |
|
Determination of ristocetin cofactor activity: eyes on both directions
|
| Montalvăo S.A.L., Annichino-Bizzacchi J.M., Pereira M.S., Machado T.M., Ozelo M.C., De Paula E.V. |
| |
|
Development and evaluation of an immunoassay for the monitoring of a new anti-platelet drug chimeric monoclonal SZ21 F(ab)2
|
| Ji S., Wen N., Li Z., Ruan C. |
| |
|
Development and validation of a complementary alternative medicine educational handout and performance evaluation tool for Anticoagulated children
|
| Bauman M.E., Mack G., Bruce A., Black K.L., Massicotte M.P. |
| |
|
Development of a clinical cut-point for a new automated D-dimer
|
| Bates S.M., Johnston M., Ali E., Ginsberg J.S. |
| |
|
Development of a convenient lectin-based method for the discrimination of plasma-derived and recombinant von Willebrand factor
|
| Weber A., Minibeck E., Turecek P.L., Ehrlich H.J., Schwarz H.P. |
| |
|
Development of a laboratory model of post cardiac coagulopathy
|
| Tang M., Christiansen K., Ingerslev J., Hjortdal V., S⊘rensen B. |
| |
|
Development of a model to study platelet function under conditions of flow
|
| Du V.X., Heijnen H.F.G., de Groot P.G., Barendracht A., Roest M. |
| |
|
Development of a novel heparanase activity assay and identification of potent heparanase inhibitors
|
| Alban S., Schiemann S. |
| |
|
Development of a novel tenase-bypassing agent with a prolonged half-life in vivo
|
| Gueguen P., Cherel G., Panicot-Dubois L., Pendu R., Badirou I., Dubois C., Denis C.V., Christophe O.D. |
| |
|
Development of a pediatric quality of life inventory for children requiring long-term anticoagulation
|
| Bruce A.A.K., Bauman M.E., Newton A.S., Bauman M., Bajzar L., Black K., Legge L., Massicotte M. |
| |
|
Development of a severe Von Willebrand facator/ADAMTS13 dysbalance during liver transplantation
|
| Pereboom I.T.A., Adelmeijer J., van Leeuwen Y., Hendriks H.G.D., Porte R.J., Lisman T. |
| |
|
Development of factor V Leiden brochure
|
| Goldsmith R.E., Chan A.K.C., Seroski W.M., Wizowski L. |
| |
|
Development of FC-gamma-RIIA antagonist
|
| Thai trung king M., Adamo M., Brennan M., Cox D. |
| |
|
Development of human artificial chromosome vectors for gene therapy of hemophilia A
|
| Yakura Y., Ishihara C., Hayashi A., Matsui T., Matsumoto S., Kurosaki H., Oshimura M., Doi T., Komatsu N., Takeya H. |
| |
|
Development of new assays to identify the CRP-VLDL complex
|
| Abrams S.T., Downey C., Thachil J., Wang G., Toh C.H. |
| |
|
Development of novel technology to analyze the process of intravascular thrombolysis
|
| Magari Y. |
| |
|
Development of rsolCD39-PSGL as a novel therapeutic with anti-thrombotic and anti-inflammatory effects
|
| Dezfouli S., Zhang X., Crikis S., Dwyer K., Selan C., Robson S., d’Apice A., Cowan P., Nandurkar H. |
| |
|
Development of thrombopoietin receptor agonists for clinical use
|
| Ikeda Y., Miyakawa Y. |
| |
|
Developmental differences in procoagulant phosholipid/microparticle concentration
|
| Summerhayes R., Ignjatovic V., Monagle P. |
| |
|
Dexamethasone induces a heat-stress response that ameliorates the conformational consequences on antithrombin of l-asparaginase treatment and helps to explain the reduced risk of thrombosis
|
| Hernández-Espinosa D., Mińano A., Ordóńez A., Mota R., Martínez-Martínez I., Vicente V., Corral J. |
| |
|
Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia
|
| Bussel J. |
| |
|
Diagnosis of deep vein thrombosis by compression ultrasonography during pregnancy and the postpartum period: a management outcome study
|
| Legal G., Righini M., Kercret G., Bressollette L., Louis P., Bohec C., Labalette M., Mottier D., Angio-Getbo Group A. |
| |
|
Diagnosis of hyperfibrinolysis : which test(s) should be used?
|
| Eeckhoudt S., Latinne D., Lambert C., Hermans C. |
| |
|
Diagnosis of nonovert, preclinical DIC using criteria from the International Society on Thrombosis and Hemostasis
|
| Lee J., Song J. |
| |
|
Diagnostic management of clinically suspected acute pulmonary embolism
|
| Huisman M.V., Klok F.A. |
| |
|
Diagnostic performance of AQT90 FLEX D-Dimer in patients suspected for deep venous thrombosis – comparison with four well-established D-dimer tests
|
| Sidelmann J.J., Gram J., Jespersen J. |
| |
|
Diagnostic performance of the VIDAS D-dimer in a prospective study of inpatients and emergency patients evaluated for pulmonary embolism with analysis of percent obstruction
|
| Courtney D.M., Klekowski N.T., Miller C.D., Smithline H.A., Hogg M.M., Kline J.A. |
| |
|
Diagnostic review of children with presumed immune thrombocytopenic purpura in the greater manchester and lancashire region (UK)
|
| Searle E.J., Will A.M., Grainger J.D. |
| |
|
Diagnostic value of platelet flow-cytometric analysis in patients with clinically relevant bleeding diathesis and unrevealing laboratory work-up
|
| Conte T., Pavicic M., Reusser M., Barizzi G., Keller P., Alberio L. |
| |
|
Dic and thrombophilia prophylaxis during chemotherapy in gynecologic cancer patients
|
| Vorobev A., Makatsaria A. |
| |
|
Differences in aetiological and clinical manifestations in upper and lower limb deep venous thrombosis patients from India
|
| Pai N., Shetty S., Kulkarni B., Ghosh K. |
| |
|
Differences in venous thromboembolism management in three European countries: results from the RIETE registry
|
| Cambou J.P., Hassairi N., Bura A. |
| |
|
Different binding characteristics of the integrin alpha 2 beta 1 due to I-domain mutations
|
| Iserbyt B.F., Staelens S., Van de Walle G.R., Salles I.S., Pareyn I., Vanhoorelbeke K., Deckmyn H. |
| |
|
Different methods of thrombin generation as a parameter to monitor patients with thrombophilia and pregnancy
|
| Siegemund A., Siegemund T., Wittig I., Scholz U. |
| |
|
Different one stage FVIII activity results in a patient with moderate haemophilia a depending on the type of aptt reagent used
|
| Brooks S.V., Aghighi S., Gomez K., Mellars G., Mathias M. |
| |
|
Different pattern of modifications for haematopoietic and endothelial progenitor cells after a strenuous exercise in sedentary healthy men
|
| Cesari F., Sofi F., Capalbo A., Pucci N., Caporale R., Gori A., Califano S., Abbate R., Gensini G. |
| |
|
Different severity of clinical manifestation in patients with severe hemophilia A
|
| Faranoush M., Danaie N., Ghorbani R., Rahmani M., Jazebi M., Shashaani T., Mehrvar A., Hedayatiasl A., Vossough P. |
| |
|
Differential activation and functional role of myosin light chain (Thr)18 and (Ser)19 phosphorylations in platelets
|
| Getz T.M., Dangelmaier C.C.D., Daniel J.J.D., Kunapuli S.S.P.K. |
| |
|
Differential effect of prophylactic or on demand treatment regimes in hemophilia A patients on TAFI activation
|
| Mikovic D., Holmström M., Woodhams B.J., Antovic J. |
| |
|
Differential effects of generic argatrobans on the PT/INR
|
| Iqbal O., Masood S., Gray A., Hoppensteadt D., Fareed J. |
| |
|
Differential effects of generic argatrobans on whole blood activation and thrombin generation markers
|
| Iqbal O., Masood S., Hoppensteadt D., Fareed J. |
| |
|
Differential effects of low-dose aspirin taken at bedtime versus on awakening on plasma-renin activity, cortisol and catecholamines in hypertensive subjects: a randomized crossover trial
|
| Snoep J.D., Hovens M.M.C., Pasha S.M., Frölich M., Pijl H., Tamsma J.T., Huisman M.V. |
| |
|
Differential effects of polyphosphate on blood clotting
|
| Smith S.A., Choi S.H., Huyck J., Morrissey J.H. |
| |
|
Differential effects of TAK-442, a factor Xa inhibitor, and ximelagatran, a thrombin inhibitor on factor V-mediated feedback on coagulation cascade and bleeding
|
| Konishi N., Hiroe K., Imaeda Y., Fujimoto T., Kubo K., Kawamura M. |
| |
|
Differential expression and secretion of tissue factor and tissue factor pathway inhibitor modulate endothelial thromboresistance in vitro
|
| Madon J., Ruf W., Valsami S., Leikauf M., Kaech A., Asmis L.M. |
| |
|
Differential impact of conventional and low dose oral hormone therapy (HT) on sex hormone binding globulin (SHBG)
|
| Eilertsen A.L., Hoibraaten E., Lofthus C.M., Mowinckel M.C., Sandset P.M. |
| |
|
Differential roles of cAMP and cGMP in megakaryocyte maturation and platelet formation
|
| Jurak Begonja A., Gambaryan S., Schulze H., Patel Hett S., Italiano J.E., Hartwig J.H., Walter U. |
| |
|
Differential roles of par-1 and par-3 in vascular endothelial cells
|
| Skok M.V., Kalashnyk O.M., Zhukova A.I., Mikhalovska L.I., Mikhalovsky S.V. |
| |
|
Differential sensitivity of the various ex vivo tests monitoring functional variability of platelet response to clopidogrel
|
| Bal dit Sollier C., Berge N., Boval B., Drouet L. |
| |
|
Differential thrombin generation inhibition by branded and generic low molecular weight heparins (LMWHs) as studied by using fluorescence substrate based kinetic method
|
| Adiguzel C., Litinas E., Cunanan J., Hoppensteadt D., Walenga J.M., Fareed J. |
| |
|
Differential transcription of MRNA coding the VWF-cleaving protease ADAMTS13 under proinflammatory stimulation in endothelial and stellate cells
|
| Claus R.A., Conradi F., Bockmeyer C.L., Kentouche K., Sieber M.W., Recknagel P., Losche W., Friedman S., Bauer M. |
| |
|
Differential VASP phosphorylation controls actin cytoskeleton remodeling
|
| Seifert S., Benz P.M., Blume C., Wilhelm S., Waschke J., Schuh K., Muenzel T., Gertler F.B., Renné T. |
| |
|
Differentiation of patients with severe hemophilia a by factor VIII activity: a mass spectrometry approach
|
| van Geffen M., Verbruggen B., Mancuso M.E., Laros-vanGorkom B., Santagostino E., van Heerde W.L. |
| |
|
Differing effects of three prothrombin complex concentrates on anticoagulated plasma as measured by calibrated automated thrombography
|
| Gilmore R.M., Harmon S., Keane G., Gannon C., Byrne M., White B., O’Donnell J.S. |
| |
|
Dimeric-specific conformation of the collagen-receptor glycoprotein (GP) VI contains the collagen-binding site of native platelets: direct evidence provided by a recombinant Fab specific for dimeric GPVI
|
| Jung S.M., Moroi M. |
| |
|
Dimerization of human factor XI is not a prerequisite for its secretion or activation
|
| Zucker M., Zivelin A., Landau M., Rosenberg N., Seligsohn U. |
| |
|
Diminished Syk phosphorylation in platelets underlies impaired thrombus growth in response to collagen in mice lacking semaphorin 4D
|
| Wannemacher K.M., Zhu L., Jiang H., Fong K., Stalker T.J., Lee D., Tran A., Neeves K., Maloney S., Kumanogoh A., Hammer D., Diamond S.L., Brass L.F. |
| |
|
Direct correlation between platelet and plasma factor V levels in homozygous and heterozygous factor V deficient subjects
|
| Spiezia L., Radu C., Tognin G., Bulato C., Florean M., Pradella P., Gavasso S., Barillari G., De Angelis V., Simioni P. |
| |
|
Direct effects of protein S in ameliorating acute lung injury
|
| Takagi T., Gabazza E.C., Morser J., Aoki S., Fujimoto H., D’Alessandro-Gabazza C.N., Toda M., Fujiwara A., Takei Y., Taguchi O. |
| |
|
Direct interaction between Galpha13 and integrin beta3 subunit mediates integrin outside-in signalling
|
| Gong H., Flevaris P., Chow C., Lam S., Voyno-Yasenetskaya T., Kozasa T., Du X. |
| |
|
Direct low-molecular FXa- and/or FIIa-inhibitors have no risk for hit type II: effects of PF4 on thrombin generation inhibited by rivaroxaban, dabigatran and new dual FIIa/FXa-inhibitors
|
| Pillitteri D., Scholz T., Westrup D., Krause M., Kirchmaier C.M. |
| |
|
Disabled-2 is a key regulator during mesodermal differentiation and megakaryopoiesis of murine embryonic stem cells
|
| Huang C., Cheng J., Lin C., Tseng C. |
| |
|
Dispersal of platelet aggregates by P2Y12 antagonist ARC-69931MX
|
| Speich H.E., Caughran J.D., Lands L.T., Jennings L.K. |
| |
|
Disruption of GATA-1/FOG-1 interaction with the NuRD complex results in a macrothrombocytopenia and absent α-granules
|
| Wang Y., Miccio A., Gregory G.D., Hong W., Blobel G.A., Poncz M. |
| |
|
Dissection of metabolic syndrome trait in Asian Indian families with strong history of coronary artery disease
|
| Shanker J., Sibi K., Hebbagodi S., Rao V.S., Dhanalakshmi B., Mani A., Kakkar V.V. |
| |
|
Disseminated intravascular coagulation syndrome in severe burns
|
| Presnyakova M.V., Sidorkina A.N., Sidorkin V.G. |
| |
|
Disseminated intravascular coagulation with a fibrinolytic phenotype modified through fibrinogenolysis at an early phase of trauma predicts mortality
|
| Gando S., Sawamura A., Hayakawa M., Kubota N., Sugano M., Wada T., Katabami K. |
| |
|
Distinct T cell and B cell immune responses in BALB/C and C57BL/6 mice influence the anti-FVIII antibody titre in hemophilia A mice
|
| Qadura M., Waters B., Burnett E., Chegeni R., Othman M., Lillicrap D. |
| |
|
Distribution of von Willebrand disease (VWD) types in 94 families from the French National Reference Center for VWD (CRMW) : type 1 is not the most frequent within ‘true’ VWD
|
| Goudemand J., Fressinaud E., Boisseau P., Ternisien C., Caron C., Trossaert M., Itzhar N., Borel-Derlon A., Dreyfus M., Boyer-Neumann C., Lambert T., Proulle V., Zawadzki C., Meyer D., Veyradier A. |
| |
|
Disturbed blood flow induces erosive injury of tissue factor-rich intima and promotes thrombus formation
|
| Sumi T., Yamashita A., Matsuda S., Nishihira K., Furukoji E., Sugimura H., Imamura T., Kitamura K., Goto S., Asada Y. |
| |
|
Divergent roles of conventional and novel PKC isoforms in platelet activation towards thrombus formation
|
| Gilio K., Harper M.T., Cosemans J.M.E.M., Hall K.J., Konopatskaya O., Munnix I.C.A., Molkentin J.D., Leitges M., Heemskerk J.W.M., Poole A.W. |
| |
|
Diverse coagulation laboratory characteristics of edta- versus citrate-anticoagulated plasma samples and a simple method to differentiate them
|
| Cardel L.K., Chen D., Pruthi R.K., Nichols W.L., Heit J.A. |
| |
|
DNAzymes to mouse beta1 integrin mRNA in vivo – targeting the tumor vasculature
|
| Sacewicz I., Wiktorska M., Wysocki T., Cierniewski C.S., Niewiarowska J. |
| |
|
Do bolus doses of UFH contribute to increased bleeding risks in children?
|
| Newall F.H., Ignjatovic V., Johnston L., Lane G., Monagle P. |
| |
|
Do human platelets have a perimembrane, extracellular Ca2 + source which can be mobilised upon thrombin stimulation?
|
| Harper A.G.S., Sage S.O. |
| |
|
Do young platelets have an enhanced capacity to expose procoagulant phosphatidylserine (PS) upon activation?
|
| Rand M.L., Wang H., Annie Bang K.W., Freedman J. |
| |
|
Does factor XI activity correlate with thrombin generation?
|
| Elreda L., Ogbata O.U., Drejka M., Cohen A.J. |
| |
|
Does hemodialysis cause blood platelets apoptosis?
|
| Sobol A., Kaminska M., Stasiak M., Szymanski J., Walkowiak B. |
| |
|
Does heterogeneity in measured calibrated thrombin generation assay or FVIII activity (<1%) explain clinical heterogeneity in severe hemophilia A?
|
| Sinclair G.D., Blanchette V., Card R.T., Chan A.K.C., Israels S., Lillicrap D., Rivard G., Robinson S., Vickars L., Williams Z., Wu J.K.M., Poon M. |
| |
|
Does patient sex and prior hormonal therapy predict risk for thrombosis recurrence after a first venous thromboembolism?
|
| Douketis J., Iorio A., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Tosetto A. |
| |
|
Does the clinical presentation of venous thromboembolism predict the risk for and type of thrombosis recurrence?
|
| Douketis J., Iorio A., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Tosetto A. |
| |
|
Does therapy of hemophilia change in the elderly?
|
| Miesbach W., Krekeler S., Asmelash G., Llugaliu B., Alesci S. |
| |
|
Domain swapping of CCR1 and CCR5 reveals defined functions of the extracellular regions in cell recruitment
|
| Koenen R.R., Kramp B.K., Sarabi A., Winkler S., Weber C. |
| |
|
Dominant inheritance of a novel integrin beta3 mutation associated with hereditary macrothrombocytopenia and platelet dysfunction
|
| Gresele P., Falcinelli E., Bury L., Giannini S., D’Adamo P., D’Eustacchio A., Corazzi T., Mezzasoma A., Di Bari F., Guglielmini G., Cecchetti L., Noris P., Balduini C., Savoia A. |
| |
|
Dose escalation of low molecular weight heparin to manage recurrent venous thromboemblic events despite systemic anticoagulation in cancer patients
|
| Carrier M., Le Gal G., Cho R., Tierney S., Rodger M.A., Lee A.Y. |
| |
|
Dose response and prolonged effect of 40K PEG-FIX on bleeding in hemophilia B mice
|
| Elm T., Oestergaard H., Tranholm M. |
| |
|
Dose response study of intra-arterial plasmin to recanalize the thrombo-occluded rabbit middle cerebral artery
|
| Jahan R., Gruber T., Goyal A., Arora V., Marder V.J. |
| |
|
Dose-dependent effects of aspirin on platelet function
|
| Sobieraj-Teague M., Weitz J.J.I., Ginsberg J.J.S., Sloane D.D., Anand S.S., Eikelboom J.J.W. |
| |
|
Dose-dependent inhibition of ex vivo fibrin formation by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation
|
| Wolzt M., Kapiotis S., Schützer K., Holmberg M., Eriksson U., Wahlander K. |
| |
|
Dosing and effectiveness of recombinant FVIIA (RFVIIA) in congenital hemophilia with inhibitors by bleed type and location: the experience of the hemophilia and thrombosis research society (HTRS) registry (2004–2008)
|
| Young G.A., Cooper D.L., Gut R. |
| |
|
Dosing and effectiveness of recombinant FVIIa (rFVIIa) in surgical and dental procedures in congenital hemophilia with inhibitors: the Experience Of The Hemophilia and Thrombosis Research Society (HTRS) Registry (2004–2008)
|
| Valentino L.A., Cooper D.L. |
| |
|
Dosing and safety of antithrombin concentrate in pediatric patients who require heparin anticoagulation
|
| Bauman M.E., Black K.L., Bruce A., Kuhle S., Bajzar L., Massicotte M.P. |
| |
|
Dosing of LMWH (enoxaparin) therapy in children
|
| Ignjatovic V., Najid S., Newall F., Summerhayes R., Monagle P. |
| |
|
Down regulation of prothrombinase activity by activated protein C measured in real-time during prothrombin activation
|
| Kim P.Y., Nesheim M.E. |
| |
|
Down regulation of the expression of key genes following treatment of breast cancer cells with heparin
|
| Scully M.F., Dawson G., Goodwin C., Razzaq T., Kakkar A.K. |
| |
|
Downregulation of MMP-7 by siRNA in cancer cells results in retardation of tumor growth and new blood vessels formation in vitro and in vivo
|
| Wysocki T., Wiktorska M., Saczewicz I., Cierniewski C.S., Niewiarowska J. |
| |
|
Down-regulation of protein s expression by 17beta-estradiol in HepG2 cells
|
| Suzuki A., Sanda N., Makita K., Miyawaki Y., Fujimori Y., Yamada T., Takagi A., Murate T., Saito H., Kojima T. |
| |
|
Downstream processing of pegylated rFVIIa
|
| Jensen O.E., Hansen T.B., Ahmadian H., Korn⊘ H.T. |
| |
|
Drug interactions of oral antithrombin and anti-Xa agents with heparinized and oral anticoagulant treated patients
|
| Masood S., Cunanan J., Hoppensteadt D., Van Thiel D., Fareed J. |
| |
|
Drug-induced antiphospholipid antibody syndrome – time to resolution
|
| Kennedy M., Dlott J.S. |
| |
|
Duodenal and gastric dieulafoy's lesions in two unrelated patients with type 2A von Willebrand's disease: is this a casual association?
|
| De Cristofaro R., Riccioni M., Basso M., Lancellotti S., Federici A., Spada C., Costamagna G., Landolfi R. |
| |
|
Duplication of exons 1 to 22 of the F8 gene: ŕ propos of a haemohilia A patient
|
| Costa C., Bieth E., Boisseau P., Letourneau S., Dastot F., Girodon E., Goossens M. |
| |
|
Duration of Anticoagulation after initial idiopathic venous thrombosis – the swinging pendulum: risk assessment to predict recurrence
|
| Eichinger S., Kyrle P.A. |
| |
|
Dynamic changes in clot elastic modulus during hemorrhagic shock in a swine model
|
| White N.J., Martin E.J., Ward K.R. |
| |
|
Dynamic upregulation of human platelet production by high shear rates
|
| Dunois-Larde C., Capron C., Fichelson S., Cramer-Borde E., Baruch D. |
| |
|
Dynamical view of membrane binding and complex formation of human tissue factor and factor VIIa
|
| Tajkhorshid E., Ohkubo Y.Z. |
| |
|
Dynamics of factor VIII C2 domain in relation to membrane binding
|
| Pantazatos D., Gessner C.R., Woods V.L., Gilbert G.E. |
| |
|
Dynamics of platelet thrombus formation
|
| Jackson S.P., Nesbitt W.S., Westein E. |
| |
|
Dynamin2- mediated caveolae internalization controls the cell surface activity of tissue factor pathway inhibitor in endothelial cells
|
| Lupu C., Popescu N.I., Silasi-Mansat R., Zhu H., Lupu F. |
| |
|
Dynorphin regulates the plasma kallikrein-kinin system function on astrocytes
|
| Mallela J., Yang J., Shariat-madar Z. |
| |
